Analyst Price Targets — STAA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 9, 2026 8:53 am | — | Canaccord Genuity | $27.00 | $25.21 | TheFly | Staar Surgical upgraded to Buy from Hold at Canaccord |
| March 4, 2026 12:39 pm | — | Stifel Nicolaus | $18.00 | $19.22 | StreetInsider | STAAR Surgical (STAA) PT Lowered to $18 at Stifel After Noisy Q4 Results |
| February 9, 2026 11:57 am | — | Stifel Nicolaus | $19.00 | $17.58 | TheFly | Staar Surgical price target lowered to $19 from $28 at Stifel |
| February 3, 2026 1:00 pm | — | Wedbush | $26.00 | $18.16 | TheFly | Staar Surgical initiated with a Neutral at Wedbush |
| January 16, 2026 11:24 am | — | Morgan Stanley | $13.00 | $20.97 | TheFly | Staar Surgical resumed with an Underweight at Morgan Stanley |
| January 15, 2026 3:17 pm | John Young | Canaccord Genuity | $22.00 | $21.02 | StreetInsider | STAAR Surgical (STAA) PT Lowered to $22 at Canaccord Genuity |
| December 10, 2025 11:53 am | Simran Kaur | Wells Fargo | $30.75 | $25.38 | TheFly | Staar Surgical price target raised to $30.75 from $28 at Wells Fargo |
| December 9, 2025 2:51 pm | John Young | Canaccord Genuity | $30.75 | $25.89 | StreetInsider | STAAR Surgical (STAA) PT Raised to $30.75 at Canaccord Genuity |
| October 21, 2025 10:40 am | John Young | Canaccord Genuity | $28.00 | $25.32 | StreetInsider | Canaccord Genuity Reiterates Hold Rating on STAAR Surgical (STAA) |
| August 7, 2025 1:01 am | Thomas Stephan | Stifel Nicolaus | $28.00 | $26.90 | TheFly | Staar Surgical downgraded to Hold from Buy at Stifel |
Latest News for STAA
STAAR Surgical (STAA) stock surged more than 25% on Thursday after the ophthalmic implant maker projected first-quarter net sales would top $90 million, more th
The major indexes are pulling back after yesterday's ceasefire-related surge
STAAR Surgical Company has seen a dramatic valuation reset, now trading at a $1bn market cap after failed acquisition talks and underwhelming US growth. Q1 2026 net sales are expected to exceed $90m, driven by a strong rebound in China and signaling potential for record annual revenues. Despite operational challenges and competitive pressures, STAA's proprietary Collamer lens and expanded US indications provide…
STAAR Surgical (STAA) expects Q1 net sales to exceed $90M, more than doubling year-over-year, driven primarily by China and double-digit growth in the Americas. Disney plans 1,000 job cuts in marketing overhaul under new CEO.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement because it expects to be interacting with…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STAA.
U.S. House Trading
No House trades found for STAA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.